These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25242760)

  • 61. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
    J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP; Xie J; Williams D; Woodman RC; Wilhelm FE
    Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epoetin alfa and intravenous iron sucrose to treat severe anemia in a patient with chronic radiation enteropathy: a case report.
    Séronie-Vivien S; Mourey L; Tohfe M; Bugat R
    Med Oncol; 2003; 20(3):301-6. PubMed ID: 14514981
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The relationship between depressive symptoms and erythropoietin resistance in stable hemodialysis patients with adequate iron stores.
    Afsar B
    Int J Artif Organs; 2013 May; 36(5):314-9. PubMed ID: 23645578
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.
    Dellanna F; Fluck RJ; Lonnemann G; Wild CA; Iwanowitsch A; Meissner R; Audhya P
    Clin Nephrol; 2015 Nov; 84(5):280-8. PubMed ID: 26396097
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Questionable conclusions about epoetin alfa.
    Kruse MW; Lee JJ
    Am J Health Syst Pharm; 2007 Sep; 64(17):1789-90; author reply 1790-1. PubMed ID: 17724355
    [No Abstract]   [Full Text] [Related]  

  • 72. Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.
    Sanz Ortiz J
    Clin Transl Oncol; 2008 Aug; 10(8):486-92. PubMed ID: 18667379
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Three-year safety observation of subcutaneous administration of epoetin-zeta in patients with chronic renal anemia: Results from PASCO II study.
    Patsialas S; Fowler H; Guilatco R; Salts S; Xia FR; Gomez Perez S; Iwanowitsch A; Kohnle M
    Clin Nephrol; 2023 May; 99(5):247-255. PubMed ID: 36871229
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
    Locatelli F; Del Vecchio L
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correction of postkidney transplant anemia reduces progression of allograft nephropathy.
    Choukroun G; Kamar N; Dussol B; Etienne I; Cassuto-Viguier E; Toupance O; Glowacki F; Moulin B; Lebranchu Y; Touchard G; Jaureguy M; Pallet N; Le Meur Y; Rostaing L; Martinez F;
    J Am Soc Nephrol; 2012 Feb; 23(2):360-8. PubMed ID: 22193388
    [TBL] [Abstract][Full Text] [Related]  

  • 76. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
    Kalantar-Zadeh K
    Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series.
    Muñoz Ramos P; Gil Giraldo Y; Álvarez Chiva V; Quiroga B
    Medwave; 2021 Oct; 21(9):e8474. PubMed ID: 34669690
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pre-Transplant Erythropoiesis-Stimulating Agent Hypo-Responsiveness and Post-Transplant Anemia.
    Kitamura K; Nakai K; Fujii H; Ishimura T; Fujisawa M; Nishi S
    Transplant Proc; 2015; 47(6):1820-4. PubMed ID: 26293057
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Posttransplantation Anemia in Kidney Transplant Recipients.
    Gafter-Gvili A; Gafter U
    Acta Haematol; 2019; 142(1):37-43. PubMed ID: 30970356
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction.
    Becker BN; Becker YT; Leverson GE; Heisey DM
    Nephrol Dial Transplant; 2002 Sep; 17(9):1667-73. PubMed ID: 12198221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.